- RESEARCH HIGHLIGHT
- 11 November 2022
In a archetypal in-human study, researchers utilized an array of technologies to make highly personalized compartment therapy products for patients with coagulated tumors.
-
Karen O’Leary
-
Karen O’Leary is an Associate Research Analysis Editor with Nature Medicine.
-
The extremity of crab immunotherapy is to harness the patient’s ain immune strategy to observe and termination tumor cells. A cardinal portion of this effect is the designation of ‘abnormal’ tumor proteins (neoantigens) by the T compartment antigen receptor (TCR), which forms the ground of TCR-engineering strategies for compartment therapy. For patients with coagulated tumors, however, the immense saltation successful neoantigens arsenic good arsenic antigen-presenting molecules is simply a large hurdle.
Access options
Subscribe to Nature+
Get contiguous online entree to Nature and 55 different Nature journal
Subscribe to Journal
Get afloat diary entree for 1 year
$99.00
only $8.25 per issue
All prices are NET prices.
VAT volition beryllium added aboriginal successful the checkout.
Tax calculation volition beryllium finalised during checkout.
Buy article
Get clip constricted oregon afloat nonfiction entree connected ReadCube.
$32.00
All prices are NET prices.
Additional entree options:
doi: https://doi.org/10.1038/d41591-022-00108-x
Related Articles
-
CAR Treg cells: premier suspects successful therapeutic resistance
-
Anti-CD19 CAR T compartment therapy for refractory systemic lupus erythematosus
-
Read much probe highlights selected by the Nature Medicine team
English (US)